Tcr2 Therapeutics Inc (NASDAQ: TCRR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $19.00 price target on the stock.
TCR2 Therapeutics Inc. (TCRR)
Last tcr2 therapeutics inc. earnings: 11/12 07:00 am
Check Earnings Report
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
TCRR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRR alerts
High impacting TCR2 Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
TCRR
News
- TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
- TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ DrugsPR Newswire
- TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRRBusiness Wire
- STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – TCRR. MPB, FRBAAccesswire
TCRR
Earnings
- 5/11/23 - Miss
TCRR
Sec Filings
- 6/1/23 - Form POS
- 6/1/23 - Form POS
- 6/1/23 - Form POS
- TCRR's page on the SEC website